The company said that $1.4 million of its second-quarter revenue was related to the sales of products and wafers to Perlegen Sciences. In Q2 of 2003, Affymetrix said that $2.8 million of its revenue was related to Perlegen sales.
Affymetrix reported revenues of $35.4 million on sales of its GeneChip microarrays and $20.1 million on instruments. The company said it increased its installed base of GeneChip systems to approximately 1,070.
The company also reported a net income of $7 million in Q2 of 2004, as compared to $5.2 million in the same quarter last year. R&D expenditures rose to $17.8 million for the second quarter from $16.6 million in Q2 of 2003.